Yifan Pharmaceutical Management
Management criteria checks 4/4
Yifan Pharmaceutical's CEO is Xian Feng Cheng, appointed in Nov 2014, has a tenure of 10.58 years. directly owns 40.82% of the company’s shares, worth CN¥6.54B. The average tenure of the management team and the board of directors is 3.1 years and 10.7 years respectively.
Key information
Xian Feng Cheng
Chief executive officer
CN¥624.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.6yrs |
| CEO ownership | 40.8% |
| Management average tenure | 3.1yrs |
| Board average tenure | 10.7yrs |
Recent management updates
Recent updates
Improved Revenues Required Before Yifan Pharmaceutical Co., Ltd. (SZSE:002019) Shares Find Their Feet
Feb 26
Yifan Pharmaceutical (SZSE:002019) Takes On Some Risk With Its Use Of Debt
Jan 30Does Yifan Pharmaceutical (SZSE:002019) Have A Healthy Balance Sheet?
Oct 11Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Could Signal Some Risk
Sep 11These 4 Measures Indicate That Yifan Pharmaceutical (SZSE:002019) Is Using Debt Extensively
Jun 04Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Shares Leap 28% Yet They're Still Not Telling The Full Story
May 08A Piece Of The Puzzle Missing From Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price
Mar 01CEO
Xian Feng Cheng (57 yo)
Mr. Xian feng Cheng serves as the Chairman of the Board of Directors at Yifan Pharmaceutical Co., Ltd and serves as its Director since October 15, 2014 and serves as its President and General Manager since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board of Directors | 10.6yrs | CN¥624.00k | 40.82% CN¥ 6.5b | |
| Financial Director | 1.9yrs | CN¥430.00k | 0.0032% CN¥ 508.2k | |
| Deputy GM | 12.6yrs | CN¥562.60k | 0.063% CN¥ 10.1m | |
| Board Secretary | no data | CN¥480.00k | 0.060% CN¥ 9.7m | |
| Deputy GM & VP | 3.1yrs | CN¥2.94m | 0.0020% CN¥ 322.2k | |
| Deputy GM & VP | 3.1yrs | CN¥1.91m | 0.0032% CN¥ 514.6k | |
| Head of Accounting | no data | no data | no data | |
| Director of Sales Team | no data | no data | no data |
Experienced Management: 002019's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board of Directors | 10.7yrs | CN¥624.00k | 40.82% CN¥ 6.5b | |
| Deputy GM | 12.6yrs | CN¥562.60k | 0.063% CN¥ 10.1m | |
| Board Secretary | 9.2yrs | CN¥480.00k | 0.060% CN¥ 9.7m | |
| Supervisor | 7.3yrs | no data | 0.000010% CN¥ 1.6k | |
| Member of the Supervisory Board | 10.7yrs | CN¥234.20k | no data | |
| Director | 10.7yrs | CN¥480.00k | 0.058% CN¥ 9.4m | |
| Director | 10.7yrs | CN¥480.00k | 0.032% CN¥ 5.2m | |
| Independent Director | 4.6yrs | CN¥100.00k | no data | |
| Independent Director | 6.2yrs | CN¥100.00k | no data |
Experienced Board: 002019's board of directors are seasoned and experienced ( 10.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/01 19:56 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Yifan Pharmaceutical Co., Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shitong Han | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Zhenghua Zhang | Founder Securities Co., Ltd. |